A hot tip for this year’s Nobel Prize in physiology or medicine was Jeffrey Gordon. (In case you missed it, the prize went to Yoshinori Ohsumi.) Over the past 15 years, Gordon has progressed an obscure study of boring gut microbes to being a nearly daily topic in the media. Although often over-hyped, gut microbes are being used, and actively explored, as exciting treatments for many common diseases.
Publicity-shy Gordon is rarely seen outside St Louis, US. Yet he saw, before anyone else, the potential of the field. He has a knack for attracting the brightest and best to his lab and is the father figure of a rapidly expanding field. His former pupils have become professorial ambassadors for the study of microbes in the US and Europe.
What makes his study of microbes worthy? The community of microbes in the human body is now known as the microbiome and 99% reside in our large intestine – made up of bacteria, viruses, fungi and protists. There are around 100 trillion of them and – excluding our red blood cells – they outnumber our human cells ten to one. They are key to digesting carbohydrates high in fibre, and producing immune-suppressing chemicals to keep allergies at bay. With 200 times more genes than us, they also produce many of our metabolites and around 25% of our vitamins as well as brain chemicals like serotonin that influence our mood.
Gordon’s interest in the possible health benefits of microbes started in the 1990s when methods of detection were primitive – based on culture methods. But with genetic techniques, the full array, diversity and therapeutic potential of the 100 trillion microbes inside us became clear to him. He was the first to explore the role microbes could play in obesity using lab mice.
In a series of experiments with his talented team he first showed that the microbes were disrupted in over-fed obese mice. But his skill and insight was in using germ-free mice who had been born and brought up in germ-free conditions to show that these effects were causal. They showed that sterile mice could eat what they liked without putting on weight. But, when inoculated with normal mouse microbes and given the same food, they put on weight. This clearly showed that microbes were crucial to digesting food. When they transplanted microbes from fat mice into skinny sterile mice they made them obese.
These pivotal experiments in sterile mice led to human faecal transplant studies by others, including a clinical trial of faecal transplants from normal donors into patients with obesity and diabetes. The study was too small to show a reduction in weight, but the diabetes improved. Other larger faecal transplant studies are underway, looking at it as a treatment for obesity and a wide range of other common diseases.
Faecal transplant is now the mainstream treatment worldwide for severe recurrent gut infections (C. difficile). Gordon’s ideas migrated from obesity in the West to curing malnutrition in African children who often died mysteriously from a deficiency disease called Kwashiorkor, despite treatment with food supplements. By studying Malawian twins, one with and one without the disease, he showed that the microbes of the affected kids had been disturbed and when transplanted from the kids into mice, stopped sterile mice gaining weight on normal diets.
Although we all have a unique microbiome that is influenced by multiple factors, our diet, our environment, diseases and even our genes, Gordon’s pioneering work has ensured that despite its complexity and our incomplete understanding, humans can now harness this novel microbiome organ to improve our health. The last big surprise Nobel winner was Barry Marshall in 2005 who bravely swallowed H. pylori microbes to prove they were bad guys and caused stomach ulcers. We now know that most microbes are our friends. Gordon and our 100 trillion hard-working microbes will have to wait for their just rewards.